GlaxoSmithKline PE Ratio 2006-2019 | GSK

Current and historical p/e ratio for GlaxoSmithKline (GSK) from 2006 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. GlaxoSmithKline PE ratio as of December 06, 2019 is 13.62.
GlaxoSmithKline PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-12-06 45.51 19.45
2019-09-30 42.68 $2.34 18.24
2019-06-30 40.02 $2.32 17.25
2019-03-31 41.79 $2.07 20.19
2018-12-31 37.66 $1.94 19.41
2018-09-30 39.12 $1.01 38.74
2018-06-30 38.79 $0.91 42.63
2018-03-31 37.13 $0.57 65.14
2017-12-31 33.12 $0.79 41.92
2017-09-30 37.37 $1.22 30.63
2017-06-30 39.19 $1.00 39.19
2017-03-31 37.88 $0.83 45.64
2016-12-31 34.13 $0.47 72.61
2016-09-30 37.78 $0.12 314.81
2016-06-30 37.56 $0.03 1252.14
2016-03-31 34.73 $0.38 91.41
2015-12-31 33.52 $5.25 6.38
2015-09-30 31.52 $6.11 5.16
2015-06-30 33.70 $6.04 5.58
2015-03-31 36.86 $6.41 5.75
2014-12-31 33.64 $1.83 18.38
2014-09-30 35.70 $2.83 12.61
2014-06-30 40.97 $3.20 12.80
2014-03-31 40.46 $3.39 11.94
2013-12-31 39.90 $3.54 11.27
2013-09-30 37.05 $2.47 15.00
2013-06-30 36.51 $2.56 14.26
2013-03-31 33.91 $2.70 12.56
2012-12-31 30.95 $2.94 10.53
2012-09-30 32.48 $3.15 10.31
2012-06-30 31.65 $3.28 9.65
2012-03-31 30.82 $3.19 9.66
2011-12-31 30.75 $3.29 9.35
2011-09-30 27.48 $2.08 13.21
2011-06-30 28.21 $2.00 14.11
2011-03-31 24.96 $1.12 22.28
2010-12-31 25.08 $0.97 25.85
2010-09-30 24.95 $2.44 10.22
2010-06-30 21.20 $2.52 8.41
2010-03-31 23.71 $3.63 6.53
2009-12-31 25.61 $3.47 7.38
2009-09-30 23.66 $3.02 7.83
2009-06-30 20.91 $3.10 6.75
2009-03-31 18.15 $3.15 5.76
2008-12-31 21.47 $3.45 6.22
2008-09-30 24.72 $3.25 7.61
2008-06-30 24.87 $3.27 7.61
2008-03-31 23.59 $3.24 7.28
2007-12-31 27.62 $3.36 8.22
2007-09-30 28.86 $3.37 8.56
2007-06-30 28.14 $3.33 8.45
2007-03-31 29.44 $3.23 9.12
2006-12-31 27.85 $3.10 8.98
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $112.414B $41.140B
GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $366.830B 15.89
Roche Holding AG (RHHBY) Switzerland $263.804B 0.00
Merck (MRK) United States $225.752B 17.49
Pfizer (PFE) United States $211.071B 12.55
Novartis AG (NVS) Switzerland $209.837B 17.71
Novo Nordisk (NVO) Denmark $135.852B 23.42
AbbVie (ABBV) United States $128.953B 10.10
AstraZeneca (AZN) United Kingdom $126.465B 22.84
Sanofi (SNY) France $116.718B 14.34
Eli Lilly (LLY) United States $113.939B 21.04
Bristol-Myers Squibb (BMY) United States $95.965B 13.42
Bayer (BAYRY) Germany $71.769B 10.63
H Lundbeck (HLUYY) Denmark $7.657B 11.05